Get started
Kiniksa Pharmaceuticals, Ltd.Kiniksa Pharmaceuticals, Ltd.Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals, Ltd.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

KNSA chart


Full chart

KNSA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.46 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.61 USD
Net income (FY)
‪−43.19 M‬ USD
Revenue (FY)
‪423.24 M‬ USD
Shares float
‪40.43 M‬
Beta (1Y)
0.58

Employees


Employees (FY)
315
Change (1Y)
+18 +6.06%
Revenue / Employee (1Y)
‪1.34 M‬ USD
Net income / Employee (1Y)
‪−137.12 K‬ USD

About Kiniksa Pharmaceuticals, Ltd.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Sanj K. Patel
Website
kiniksa.com
Headquarters
London
Founded
2024
ISIN
GB00BRXB0C07
FIGI
BBG00KT2KFX7
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

KNSA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as KNSA.

Frequently Asked Questions


The current price of KNSA is 20.02 USD — it has decreased by −0.79% in the past 24 hours. Watch Kiniksa Pharmaceuticals, Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kiniksa Pharmaceuticals, Ltd. stocks are traded under the ticker KNSA.
KNSA stock has risen by 1.62% compared to the previous week, the month change is a −15.22% fall, over the last year Kiniksa Pharmaceuticals, Ltd. has showed a 17.08% increase.
We've gathered analysts' opinions on Kiniksa Pharmaceuticals, Ltd. future price: according to them, KNSA price has a max estimate of 40.00 USD and a min estimate of 30.00 USD. Watch KNSA chart and read a more detailed Kiniksa Pharmaceuticals, Ltd. stock forecast: see what analysts think of Kiniksa Pharmaceuticals, Ltd. and suggest that you do with its stocks.
KNSA reached its all-time high on Sep 20, 2018 with the price of 32.88 USD, and its all-time low was 5.01 USD and was reached on Oct 17, 2019. View more price dynamics on KNSA chart.
See other stocks reaching their highest and lowest prices.
KNSA stock is 4.18% volatile and has beta coefficient of 0.58. Track Kiniksa Pharmaceuticals, Ltd. stock price on the chart and check out the list of the most volatile stocks — is Kiniksa Pharmaceuticals, Ltd. there?
Today Kiniksa Pharmaceuticals, Ltd. has the market capitalization of ‪1.46 B‬, it has increased by 7.08% over the last week.
Yes, you can track Kiniksa Pharmaceuticals, Ltd. financials in yearly and quarterly reports right on TradingView.
Kiniksa Pharmaceuticals, Ltd. is going to release the next earnings report on May 6, 2025. Keep track of upcoming events with our Earnings Calendar.
KNSA earnings for the last quarter are −0.12 USD per share, whereas the estimation was 0.024 USD resulting in a −598.59% surprise. The estimated earnings for the next quarter are 0.15 USD per share. See more details about Kiniksa Pharmaceuticals, Ltd. earnings.
Kiniksa Pharmaceuticals, Ltd. revenue for the last quarter amounts to ‪122.54 M‬ USD, despite the estimated figure of ‪123.42 M‬ USD. In the next quarter, revenue is expected to reach ‪132.09 M‬ USD.
KNSA net income for the last quarter is ‪−8.89 M‬ USD, while the quarter before that showed ‪−12.69 M‬ USD of net income which accounts for 29.98% change. Track more Kiniksa Pharmaceuticals, Ltd. financial stats to get the full picture.
No, KNSA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 23, 2025, the company has 315 employees. See our rating of the largest employees — is Kiniksa Pharmaceuticals, Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Kiniksa Pharmaceuticals, Ltd. EBITDA is ‪−43.92 M‬ USD, and current EBITDA margin is −10.38%. See more stats in Kiniksa Pharmaceuticals, Ltd. financial statements.
Like other stocks, KNSA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kiniksa Pharmaceuticals, Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kiniksa Pharmaceuticals, Ltd. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kiniksa Pharmaceuticals, Ltd. stock shows the neutral signal. See more of Kiniksa Pharmaceuticals, Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.